Tag Archives: PFE stock

Pfizer (PFE) reported 24Q3 revenues of $17.7 billion, up 33.8% from 23Q3, and 13% above my estimate.  The key driver of the revenue beat came from Paxlovid, which posted sales of $2.7 billion, beating my estimate of $400 million.  GAAP … Continue reading →

Pfizer (PFE) reported 24Q2 revenues of $13.3 billion, up 4% from 23Q2, but 4.5% below my estimate.  The shortfall from projections was due mostly to lower than expected sales of Comirnaty, Prevnar, Paxlovid and Abrysvo.  Pfizer’s GAAP EPS was $0.01, … Continue reading →